Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Anti-TNF switching: effect on outcomes in patients with RA

Nature Clinical Practice Rheumatology volume 3, pages 430–431 (2007)Cite this article

boxed-textHyrich KL et al. (2007) Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56: 13–20

If a patient experiences treatment failure with one anti-TNF agent because of lack of efficacy or adverse effects, physicians should not discount the use of other drugs in this class

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yazici Y et al. (2005) Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 64: 207–211

    Article  CAS  Google Scholar 

  2. Lindberg J et al. (2006) Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 8: R179

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. University of Texas Southwestern Medical School, Division of Rheumatic Diseases, Department of Internal Medicine, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA nancy.olsen@utsouthwestern.edu

Authors and Affiliations

  1. N Olsen is a Professor of Medicine in the Division of Rheumatic Diseases, at the University of Texas Southwestern Medical School, Dallas, Texas, USA.,

    Nancy Olsen

Authors
  1. Nancy Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Nancy Olsen is an equity holder of Arthrochip LLC, and she provides research support to Bristol-Myers Squibb and Genentech.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olsen, N. Anti-TNF switching: effect on outcomes in patients with RA. Nat Rev Rheumatol 3, 430–431 (2007). https://doi.org/10.1038/ncprheum0535

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0535

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing